BioFire Boosts BioMerieux Q1 Revenues; Biodefense Contract on Hold due to Focus Dx Legal Protest | GenomeWeb

NEW YORK (GenomeWeb) — BioMérieux said this week that its first quarter revenues increased 3 percent year over year but 8 percent when including sales from recent acquisition BioFire Diagnostics and at constant exchange rates.

In addition, PCR Insider has learned that a contract awarded by the US military to recently formed BioMérieux subsidiary BioFire Defense to develop a biothreat detection platform has been put on hold due to a formal legal protest by Focus Diagnostics, which competed with BioMérieux for the contract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.